Ann: Compelling results for 2591 dose ranging study in PMS model, page-32

I was re-reading the release and paused to reflect on the deeper meaning in this statement linking Shank 3 with autism:



So down the rabbit hole I went and this is what i found on one page re: Shank 3 - https://www.spectrumnews.org/wiki/shank3/




Clearly, Glutamate signalling is core business in effective neural functioning.

This is from the slightly dated (2011) text: The Handbook of Neuroprotection by K.K. Jain (google it) page 68...



More importantly and recently, there are numerous references on Neuren's site, but the MST Access report IMO says it quite succinctly:


http://www.neurenpharma.com/irm/PDF/1892_0/MSTAccessinitiationreport14Nov2019


And finally, but not frivolously, something about the mice (the whole link is worth a squiz IMO) :

https://www.spectrumnews.org/news/researchers-debut-autism-mouse-model-lacking-shank3/

To selectively quote...


My conclusion is that we should stay quite focussed on the value in Neuren's molecules for their broader impact on autism while they pursue particular important results for identified cohorts like Rett's, PMS, Fragile X, Angelman and so on.